3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
CNS
1
Conditions
Meningeal Carcinomatosis
2
Carcinoma, Non-Small-Cell Lung
2
Brain Neoplasms
2
Respiratory Tract Diseases
1
Neoplasms
1
Lung Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
19
Radiosurgery
16
Radiotherapy
14
Specimen Handling
11
Pemetrexed
8
Paclitaxel
6
Erlotinib Hydrochloride
6
Docetaxel
6
Carboplatin
6
Bevacizumab
5
pembrolizumab
4
Temozolomide
4
Spinal Puncture
4
Cisplatin
4
osimertinib
3
Taxes
3
Nivolumab
3
Gemcitabine
3
Gefitinib
3
Filgrastim
3
Drug Therapy
3
trametinib
2
selpercatinib
2
sapanisertib
2
motexafin gadolinium
2
epothilone B
2
dabrafenib
2
X-Rays
2
Vorinostat
2
Trastuzumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
AZD3759
×
CNS
×
Clear all
NCT03653546
2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3
Completed
492 enrolled